AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01807858 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: İnulin
Description: 900 mg inulin per day will be given
Study NCT02825225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20 core-biopsy fragments
Description: Using the extended sextant fashion prostate biopsy, this randomized group was submitted to a 20-fragments core-biopsy to evaluate the diagnostic power, pain perception and complications comparative to institution's standard 12 cores.
Study NCT02825225 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Base and apex local anesthesia
Description: Using the institution's standard local anesthesia protocol (base injection) as active comparator group, this randomized group was submitted to base and apex local anesthetic application to evaluate tolerability of the procedure, pain perception (with use of previous validated analogue pain scale) and complications.
Study NCT01885845 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Excellent BRASSS-V Drape™.
Description: Immediately after delivery and cord clamping, blood measurement will begin. The calibrated delivery drape should be placed under the buttocks of the woman and tied around the woman's waist with the funnel portion hanging down between her legs. Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped.
Study NCT01885845 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Indirect weight assesment of blood loss
Description: Just after delivery and cord clamping, a sheet with plastic backing will be placed under the buttocks of the woman. A basin will be placed directly under her on a small shelf on the delivery table. Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped.~After bleeding has stopped, all gauze pieces and mops will be counted and then placed in the collection basin. The basin will be placed on the scale and weighed. The weight of the blood will be assessed by subtracting the weight of the basin, gauzes and mops from the total weight of the soaked materials assuming that one gram is equivalent to 1 ml.
Study NCT04307316 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACBT group
Description: ACBT:~Breathing control 3 to 4 Thoracic Expansion Exercise A: 3 seconds hold B: Chest clapping C: Chest vibration Forced Expiratory Technique Breathing control A: 3 seconds hold B: Chest clapping C: Chest vibration 3 to 4 Thoracic Expansion Exercise Breathing control 1-2 Huff combine with breathing control Huff and cough~Chest Physical Therapy Early mobilization
Study NCT04307316 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical therapy
Description: Chest percussion, deep breathing, Huff and cough. Early mobilization
Study NCT03493269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1834845
Description: Orally administered.
Study NCT03493269 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Orally administered.
Study NCT03493269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Part 1: Orally administered 1mg as a single dose.
Study NCT03493269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Part 1: Orally administered 1mg as a single dose.
Study NCT01095926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: blood sampling before, during and after doxorubicin administration
Study NCT01064596 — intervention group
Intervention type: OTHER
Intervention: blood samples
Description: patients with a fondaparinux treatment who have 4 blood samples during the 10 days following surgery
Study NCT02497339 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Description: Using mindfulness training (Thinking and Yoga class) to help women smokers in workplaces to quit smoking
Study NCT01287286 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AC-Can
Description: Antrodia cinnamomea compounds of 15 milliliters liquid per pack, oral post meal, twice in a day for 30 days
Study NCT01287286 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo of 15 milliliters liquid per pack, oral post meal, twice in a day for 30 days
Study NCT03356665 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rapid diagnostic test (RDT)
Description: The 4 rapid diagnostic tests (RDT) will be carried out on fresh blood from clinical suspects. Only those subjects that are positive in at least 1 RDT will 1) undergo tests on DBS (immune trypanolysis, ELISA and DNA detection); 2) undergo parasitological confirmation (reference standard) at inclusion.
Study NCT03356665 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serological and molecular tests on DBS
Description: Serological and molecular reference tests on dried blood spots (DBS) are carried out on RDT positive clinical suspects, which also undergo parasitological examination at inclusion (reference standard). If at least one of the serological or molecular reference tests on dried blood spots is positive, parasitological examination is repeated 3 and 6 months after inclusion. The combined results of parasitological examinations (at inclusion and if applicable at 3 and 6 months) serve as reference standard
Study NCT03617133 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Reduction of vaginal source loading
Description: A multicenter investigation in 50 EMBRACE patients from 3 institutions (Mohamed SM. et al, in submission 2015) shows that reduced loading in ring/ovoids and increased loading in tandem (and needles when available) can be applied without compromising CTVHR and GTVres dose. Decrease of relative vaginal loading from a mean of 50% to 33% had potential to reduce ICRU recto-vaginal dose by a mean of 4±4Gy, and furthermore, bladder and rectum doses could be reduced by 2-3Gy with the same re-arrangement of loading. Similar evidence is available from a study on simulation of different intracavitary standard loading patterns in EMBRACE patients, where it was shown that limited size tumours could often be covered by tandem loading alone (Nkiwane KS. et al. 2013).
Study NCT00457769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil and self-generated memory training
Description: Aricept 5 mg PO qd for 4 weeks followed by Aricept 10 mg PO qd for 8 weeks
Study NCT00457769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil and experimenter-administered memory training
Description: Aricept 5 mg PO daily for 4 weeks followed by Aricept 10 mg PO qd for 8 weeks
Study NCT02630719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol eye drops
Description: eye drops
Study NCT02630719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artificial tears
Description: Placebo drop
Study NCT02881086 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PEG-Asparaginase
Study NCT04133740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Liberal versus conservative oxygen therapy.
Study NCT04700930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBD-Cigarettes
Description: CBD-Cigarettes instead of normal Cigarettes: The participants in this arm receive CBD-Cigarettes which are then inhaled/smoked instead of their normal tobacco cigarettes
Study NCT04379349 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS text messaging - interactive check-in
Description: Interactive SMS text message check-ins delivered once weekly to participants.
Study NCT04379349 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: SMS text messaging - inactive control
Description: Minimally interactive SMS text message delivered once weekly to participants.
Study NCT05110391 — intervention group
Intervention type: DRUG
Intervention: Hormonal Therapy Agent
Description: Consecutive patients with NOA and hypogonadism (defined by baseline total testosterone levels equal or below 350 ng/dL) subjected to microdissection testicular sperm extraction who received or not pre-sperm retrieval gonadotropin therapy.
Study NCT01247337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin, capecitabine, gemcitabine, cetuximab
Description: Intrahepatic oxaliplatin
Study NCT01247337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin, capecitabine, gemcitabine cetuximab
Description: Oxaliplatin given intravenous
Study NCT02307565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine
Description: Each arm (2) will last 30 days with a 14 day washout in between each arm. Subjects nor the investigators will know which drug (midodrine or placebo) is administered to the subject for the first arm (30 days) and the second arm (30 days). The subjects will take a pill three times a day. Each subject will return home with a blood pressure monitor and will be asked to report his/her blood pressure at least 3 times a day and complete questionnaires based on how he/she is feeling.
Study NCT02307565 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midodrine
Description: Each arm (2) will last 30 days with a 14 day washout in between each arm. Subjects nor the investigators will know which drug (midodrine or placebo) is administered to the subject for the first arm (30 days) and the second arm (30 days). The subjects will take a pill three times a day. Each subject will return home with a blood pressure monitor and will be asked to report his/her blood pressure at least 3 times a day and complete questionnaires based on how he/she is feeling.
Study NCT02307565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Each arm (2) will last 30 days with a 14 day washout in between each arm. Subjects nor the investigators will know which drug (midodrine or placebo) is administered to the subject for the first arm (30 days) and the second arm (30 days). The subjects will take a pill three times a day. Each subject will return home with a blood pressure monitor and will be asked to report his/her blood pressure at least 3 times a day and complete questionnaires based on how he/she is feeling.
Study NCT02307565 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each arm (2) will last 30 days with a 14 day washout in between each arm. Subjects nor the investigators will know which drug (midodrine or placebo) is administered to the subject for the first arm (30 days) and the second arm (30 days). The subjects will take a pill three times a day. Each subject will return home with a blood pressure monitor and will be asked to report his/her blood pressure at least 3 times a day and complete questionnaires based on how he/she is feeling.
Study NCT02965248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard adjuvant systemic chemotherapy
Description: Patients undergo radical surgery with standard adjuvant systemic chemotherapy (mFOLFOX6/CapeOx/sLV5FU2/Cape).~mFOLFOX6: oxaliplatin 85 mg/m2 IV d1 + leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 continuous IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles.~CapeOx: oxaliplatin 130 mg/m2 IV d1 + capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles.~sLV5FU2: leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles.~Cape: capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles.
Study NCT02965248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard adjuvant systemic chemotherapy
Description: Patients undergo radical surgery with standard adjuvant systemic chemotherapy (mFOLFOX6/CapeOx/sLV5FU2/Cape).~mFOLFOX6: oxaliplatin 85 mg/m2 IV d1 + leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 continuous IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles.~CapeOx: oxaliplatin 130 mg/m2 IV d1 + capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles.~sLV5FU2: leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles.~Cape: capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles.
Study NCT02965248 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperthermic intraperitoneal chemotherapy (HIPEC) with raltitrexed
Description: Raltitrexed (3 mg/m2) is added to the perfusate after attaining 42 degrees of inflow temperature and last for 60 minutes.
Study NCT02965248 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin
Description: Before the beginning of HIPEC, 5-FU 400 mg/m2 and leucovorin calcium 20 mg/m2 will be administered intravenously to potentiate oxaliplatin activity. Oxaliplatin (130 mg/m2) is added to the perfusate after attaining 42 degrees inflow temperature with a total of 30 minutes perfusion time.
Study NCT04033432 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant EphB4-HSA Fusion Protein
Description: Given IV
Study NCT03010553 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Detection and resection of sentinel lymph node
Study NCT03110458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SENS-111 100mg
Description: SENS-111 100mg is presented as 1 Oral Dispersible Tablet of SENS-111 100mg + 1 Oral Dispersible Tablet of placebo given twice on Day 1, second intake given approximately 12 hours (9 to 15 hours) after the first intake and thereafter given once daily on Days 2 to 5 inclusive. The corresponding total dose will be 500 mg for the entire study.
Study NCT03110458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SENS-111 200mg
Description: SENS-111 200mg is presented as 2 Oral Dispersible Tablet of SENS-111 100mg given twice on Day 1,second intake given approximately 12 hours (9 to 15 hours) after the first intake and thereafter given once daily on Days 2 to 5 inclusive. The corresponding total dose will be 1000 mg for the entire study.
Study NCT03110458 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo is presented as 2 Oral Dispersible Tablets of placebo given twice on Day 1, second intake given approximately 12 hours (9 to 15 hours) after the first intake and thereafter given once daily on Days 2 to 5 inclusive. The corresponding total dose will be 0 mg for the entire study.
Study NCT03903900 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle-oriented Occupational Therapy added to current treatment of chronic non-malignant pain
Description: The participants are recruited from the outpatient cohort admitted at The Multidisciplinary Pain Center (MPC) at Naestved Hospital (Zealand Region, Denmark). The participants receive both, the current treatment based on Cognitive Behavioural Therapy (CBT) and delivered by physicians, nurses, physical therapists and a social worker as usual care, and a lifestyle-oriented Occupational Therapy intervention. The Occupational Therapy intervention targets meaningful daily occupations, physical activity, and eating habits and routines. The intervention is delivered by graduated occupational therapists once á week during the 15 weeks after the initial 5-weeks compulsory psychoeducation course at the MPC. The intervention contains in-person contacts with OTs every other week (e.g. two 1-hour individual sessions at the hospital and/ or at-home and five 2-hours group sessions) and seven phone consultations in the opposite weeks.
Study NCT02104648 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo RO4602522
Description: Daily oral doses
Study NCT02104648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo RO4602522
Description: Daily oral doses
Study NCT02104648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4602522
Description: Daily oral doses
Study NCT02104648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4602522
Description: Single, oral dose
Study NCT02104648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: 400 mg oral dose given on Day 1 or 11
Study NCT02104648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: moxifloxacin placebo
Description: Dose given orally on Days 1 and/or 11
Study NCT00558363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avodart
Description: 0.5 mg administered orally once daily
Study NCT00558363 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients will be randomized at Visit 2 in 1:1 ratio to receive either 0.5 mg dutasteride or placebo
Study NCT02817984 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acellular Adipose Tissue (AAT)
Description: The components of the adipose-derived scaffold are all naturally occurring AAT proteins and proteoglycans that provide a natural scaffold. The nature of the AAT also enhances host tissue integration since matrix components can be easily degraded by cell-secreted enzymes as tissue remodeling takes place. Mechanisms for matrix turnover are already established in host cells, avoiding any concerns over proper clearance of scaffold materials from the body.
Study NCT01374893 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The intervention group will perform the multi-session per day training program
Study NCT01374893 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Usual care
Study NCT03617133 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Systematic utilisation of IMRT
Description: Many institutions deliver 3D conformal radiotherapy (3D CRT) based on a four-field box technique although IMRT has been available for a number of years. The practice in EMBRACEI has been utilisation of IMRT and 3D CRT in 27% and 73% of the patients, respectively. However, EMBRACE morbidity data as well as data published by Mundt et al (Mundt AJ. et al. 2003) indicate that IMRT significantly reduces the incidence of bowel morbidity, and therefore IMRT is considered as instrumental for reducing the incidence of bowel morbidity and with a potential also to be beneficial for urinary morbidity.
Study NCT03617133 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Utilisation of daily IGRT (set-up according to bony structures)
Description: PTV margins of 10 mm to the elective lymph node target are currently applied in many institutions. This margin is related to set-up uncertainties with patient positioning performed based on skin marks. However, currently, most institutions have in-room imaging available which makes it possible to perform daily imaging and couch correction according to fusion on bony anatomy. With daily imaging, bony image fusion, and couch correction, a margin reduction from 10mm to 5mm can be performed without compromising target coverage (Laursen LV. et al. 2012). The 5mm margin reduction has potential to decrease the volume irradiated to 43Gy by approximately 500cm, which is expected to decrease bowel morbidity by \~50%.
Study NCT03617133 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: EBRT target concept related to the primary tumor (CTV-T) and internal motion; concepts for OAR contouring
Description: New target concepts are introduced for EBRT related to primary tumor: initial CTV-T, initial CTV-HR, initial CTV-LR and ITV-LR. Use of this novel contouring approach in conjunction with available MRI allows to target safely the visible tumor (CTV-T) and the high risk region (CTV-HRintitial) while consenting for dose to a low risk region (CTV-LRinitial). Anatomical changes due to organ filling variation and cervix/uterus position are considered. ITV-LR is outlined using planning scan and MR images in patients with MRI in treating position while a fixed margin is added to the CTV-LR initial in patients with only diagnostic MRI. New concepts are introduced for OAR contouring. Bowel loops are outlined in one volume restricted to the outer contour, including the mesenterium, for better approximation of the bowel volume and dose constraints. Rectum/sigmoid structures are contoured distinctly. Vaginal lower border is 2,5cm from the caudal extend of the tumor (2cm ITV-LR initial + 0,5cm PTV).
Study NCT03617133 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: EBRT dose prescription and reporting
Description: There is currently a significant variation with regard to EBRT dose and fractionation in the EMBRACE study with doses ranging from 45Gy to 50Gy and being delivered in 25-30 fractions. Furthermore, there is a wide variety of lymph node boosting strategies. In EMBRACEII, the EBRT dose and fractionation to the elective lymph node CTV and initial CTV-T is fixed at 45Gy in 25 fractions, and lymph node boosting must be performed as a simultaneous integrated boost. The dose de-escalation from 50Gy to 45Gy has potential to reduce morbidity. A system of reporting dose to targets and OARs is introduced in terms of dose volume parameters and a system of point dose reporting for the vagina.
Study NCT03617133 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Adaptation of EBRT nodal elective CTV according to risk of nodal and systemic recurrence
Description: EMBRACEII applies a risk adapted target concept for nodal CTV. This target concept is based on pattern of nodal recurrence analysis which shows 50% of recurrences beyond the classical L5/S1 cranial pelvic field border. A target volume Large Pelvis is defined for intermediate risk patients and includes internal, external, common iliac, obturator and presacral nodes. For high risk patients, defined as common iliac or >2 nodes involved, the para-aortic region is included. For low risk patients, defined as stage IA/IB1/IIA1, N0, small cell carcinoma (SCC), no uterine invasion, Small Pelvis is defined which is Large Pelvis without common iliac nodes. Intermediate risk is defined as not high and not low risk.